



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 24-06-2009

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE WEEKENDING 12-06-2009 TO BE PUBLISHED 25-06-2009 IN THE GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

### 08-06-2009

495/2009	Syngenta Limited, United Kingdom (Priority 10-06-2008 UK)	“Novel Herbicides”
496/2009	Syngenta Participations AG, Switzerland Syngenta Limited, United Kingdom (Priority 09-06-2008 UK)	“Weed control method and herbicidal composition”
497/2009	Syngenta Participations AG, Switzerland Syngenta Limited, United Kingdom (Priority 09-06-2008 UK)	“Herbicide composition”
498/2009	Sanofi-Aventis, France (Priority 09-06-2008 Europe)	“Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals”
499/2009	Sanofi-Aventis, France (Priority 10-06-2008 Europe)	“Use of dronedarone for the preparation of a medicament intended for use in the prevention of permanent atrial fibrillation”
500/2009	DyStar Textilfarben GmbH, Germany (Priority 09-06-2008 Germany)	“Dyeing warp yarns with leucoindigo foam”
501/2009	Sanofi-Aventis, France (Priority 09-06-2008 Europe)	“Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals”
502/2009	Sanofi-Aventis, France (Priority 10-06-2008 Europe)	“Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion”

503/2009	Sanofi-Aventis, France (Priority 09-06-2008 Europe)	“Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals”
504/2009	Palatin Technologies, Inc., USA (Priority 09-06-2008 USA)	“Melanocortin receptor-specific peptides for treatment of obesity/ 669”.
<b><u>09-06-2009</u></b>		
505/2009	AstraZeneca AB, Sweden (Priority 11-06-2008 USA)	“Chemical compounds -366”
506/2009	Les Laboratoires Servier, France (Priority 20-06-2008 France)	“New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.”
507/2009	Pioneer Hi-Bred International, Inc., USA (Priority 11-06-2009 USA)	“Novel bacillus thuringiensis gene with lepidopteran activity”
<b><u>10-06-2009</u></b>		
508/2009	SECRET	SECRET
509/2009	SECRET	SECRET
510/2009	SECRET	SECRET
511/2009	SECRET	SECRET
512/2009	Retractable Technologies, Inc., USA Thomas j. shaw, USA (Priority 10-06-2008 USA)	“Fluid flow control device with retractable cannula”
513/2009	United Promotions, Inc., USA (Priority 13-06-2008 USA)	“Biocide compositions comprising quaternary ammonium and urea and methods for their use”
514/2009	Schering Corporation, USA (Priority 13-06-2008 USA)	“Tricyclic indole derivatives and methods of use thereof”

515/2009	Bayer CropScience AG, Germany (Priority 13-06-2008 Europe)	“Novel amides and thioamides as pesticides”
516/2009	Sanofi-Aventis, France (Priority 12-06-2008 France)	“Azacarboline derivatives, preparation and therapeutic use thereof”
	<b><u>11-06-2009</u></b>	
517/2009	Telefonaktiebolaget Lm Ericsson (publ), Sweden (Priority 13-06-2008 USA)	“Method and arrangement in a telecommunication system”
518/2009	Sanofi-Aventis, France (Priority 13-06-2008 France)	“2-oxoalkyl-1-piperazin-2-one derivatives, preparation thereof and therapeutic use thereof”
519/2009	Sanofi-Aventis, France (Priority 13-06-2008 France)	“Novel (bridged piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors”
520/2009	Pharmasset, Inc. USA (Priority 11-06-2008 USA)	“Nucleoside cyclicphosphates”
521/2009	Eli Lilly and Company, USA (Priority 24-05-2001 USA) Divisional.	“Pharmaceutically acceptable salts of a substituted pyrazole compound”
522/2009	Marathon GTF Technology, Limited, USA (Priority 13-06-2008 USA)	“Processes for converting gaseous alkanes to liquid hydrocarbons”
523/2009	Marathon GTF Technology, Limited, USA (Priority 13-06-2008 USA)	“Bromine-based method and system for converting gaseous alkanes to liquid hydrocarbons using electrolysis for bromine recovery”
524/2009	Marathon GTF Technology, Limited, USA (Priority 13-06-2008 USA)	“Hydrogenation of multi-brominated alkanes”
525/2009	Glaxo Group Limited, United Kingdom (Priority 13-06-2008 USA)	“Pharmaceutical Formulations”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.



841/2001 Vertex  
Pharmaceuticals  
Incorporated,  
USA

“A peptidomimetic compound a pharmaceutical composition comprising thereof”

A61K 13/00

**140105**

The present invention relates to peptidomimetic compound of formula



useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; The invention is also directed to pharmaceutical composition and to method for using the compound for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the

infection. Also provided are pharmaceutical combination comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and method for treating or preventing a HCV infection in a patient using the compositions.

561/2002 Daiichi Sankyo  
Company, Limited,  
Japan

“A diamine compound”


CO7D 503/04

**140106**

A compound, represented by the formula (1):



wherein  $R^1$  and  $R^2$  are hydrogen atoms or the like;  $Q^1$  is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like;  $Q^2$  is a single bond or the like;  $Q^3$  is a group



in which  $Q^5$  is an alkylene group having 1 to 8 carbon atoms, or the like; and  $T^0$  and  $T^1$  are carbonyl groups or the like; a solvate thereof, or an N- oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory reaction syndrome (SIRS), multiple organ disease syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood gathering.


662/2002 AstraZeneca AB,  
Sweden

“Theinopyrimidinedione”

CO7D 495/04

**140107**

The invention relates to a compound of formula (1);



Whrein:

R<sup>1</sup> and R<sup>2</sup> each independently represent a C<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkenyl, C<sub>3-5</sub>cycloalkylC<sub>1-3</sub>alkyl or C<sub>3-6</sub>cycloalkyl; each of which may be optionally substituted by 1 to 3 halogen atoms; R<sup>3</sup> is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazin-2-ylcarbonyl wherein each ring is optionally substituted by one hydroxy group; Q is -CO- or -C(R<sup>4</sup>)(R<sup>5</sup>)- (wherein R<sup>4</sup> is a hydrogen atom or C<sub>1-4</sub>alkyl and R<sup>5</sup> is a hydrogen atom or hydroxy group); Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms maybe heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relate to pharmaceutical composition containing and method of using the compound of the formula (1), particularly in the modulation of autoimmune disease.

1121/2002 Merck Patent  
Gesellschaft Mit  
Beschränkter  
Haftung Darmstadt,  
Germany

“Lyophilised composition comprising antibodies”

A61K 39/395

**140108**

The invention relates to a lyophilised pharmaceutical composition comprising an antibody against the endothelial growth factor receptor (EGF receptor). The composition has increased storage stability, even at elevated temperatures, and, after reconstitution, can be used parenterally for the treatment of tumours.

396/2003 Bayer  
Aktiengesellschaft,  
Germany

“Hydroxy tetrahydro-naphthalenylurea compound”

CO7C 275/42

**140109**

This invention relates to tetrahydro-naphthalene compound which is useful as an active ingredient of pharmaceutical composition. The tetrahydro-naphthalene compound of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD.


535/2005 Wyeth,  
USA

“2-amino-3,4-dihydro-5,5-diphenylimidazole”

CO7D 401/10

**140110**

The present invention provides a compound of formula 1 and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated  $\beta$ -amyloid deposits or  $\beta$  amyloid levels in a patient.




1397/2006 Daiichi Sankyo  
Company Ltd.,  
Japan

“A diamine compound”

CO7D 503/04

140111

A compound represented by the general formula (4):



wherein


$\text{R}^1$  represents a hydrogen atom;

$\text{R}^2$  represents a hydrogen atom;


$\text{T}^1$  represents group  $-\text{C}(=\text{O})-\text{C}(=\text{O})-\text{N}(\text{R}')-$  group  $-\text{C}(\text{HS})-\text{C}(=\text{O})-\text{N}(\text{R}')-$ , or group

$-\text{C}(=\text{O})-\text{C}(=\text{S})-\text{N}(\text{R}')-$ , in which  $\text{R}'$  means a hydrogen atom or alkyl group;

$\text{Q}^3$  represents the following group:



in which  $\text{Q}^5$  is an alkylene group having 3 to 4 carbon atoms or  $-\text{CH}_2-\text{NH}-(\text{CH}_2)_2-$ ,  $\text{R}^3$  is a hydrogen atom, N, N-dialkylcarbamoyl group or alkoxyacyl group, and  $\text{R}^4$  is a hydrogen atom; and  $\text{Q}^4$  represents



1398/2006 Daiichi  
Pharmaceutical Co.  
Limited,  
Japan


“A salt or solvate of a diamine compound”

CO7D 503/04

140112

A compound represented by the general formula (1):  $\text{Q}^1-\text{Q}^2-\text{T}^0-\text{N}(\text{R}^1)-\text{Q}^3-\text{N}(\text{R}^2)-\text{T}^1-\text{Q}^4$  (1) wherein  $\text{R}^1$  and  $\text{R}^2$  are hydrogen atoms or the like;  $\text{Q}^1$  is a saturated or unsaturated, 5- or 6- membered cyclic

hydrocarbon group which may be substituted, or the like;  $Q^2$  is a single bond or the like;  $Q^3$  is a group



in which  $Q^5$  is an alkylene group having 1 to 8 carbon atoms, or the like; and  $T^0$  and  $T^1$  are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory reaction syndrome (SIRS), multiple organ disease syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood gathering.


620/2007 Sanofi-Aventis,  
France

“Substituted carbo and hetrocyclic spiro nitrile compound”

CO7D 211/66, CO7P 213/26, A61P 35/00

**140113**

The invention relates to substituted heterocyclic spiro compound of the formula 1



which inhibit cathepsins, to process for its preparation.

839/2007 Spray Engineering  
devices Limited,  
India

“Improved distributor for falling film evaporator”

BO1D 1/06. F28D 3/04

**140114**

The present invention discloses an improved distribution device for falling film evaporators adapted to swirl the feed material in the evaporator tubes, which is energy efficient cost effective, and has features, which permit quick and easy maintenance. This has been achieved by modifying the design of the distributing device by utilizing the natural flow characteristics of fluids. Apart from benefits of energy saving, use of feed material with higher content of dissolved solids and suspended particulate matter has become possible because the areas prone to scaling and clogging leading to frequent malfunctioning of the evaporator have been totally avoided.

1191/2007 Vertex  
Pharmaceuticals  
Incorporated,  
USA

“A pharmaceutically acceptable salt or prodrug of a peptidomimetic”

A61K 13/00

**140115**

The present invention relates to peptidomimetic compound of formula useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; The invention is also directed to pharmaceutical composition and to method for using the compound for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combination comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compound having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also used for treating or preventing HCV infection in a patient.


1192/2007 Vertex  
Pharmaceuticals  
Incorporated,  
USA

“A peptidomimetic compound, process for its preparation and a pharmaceutical composition comprising thereof”

A61K 13/00

**140116**

The present invention relates to peptidomimetic compound of formula I



useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; The invention is also directed to pharmaceutical composition and to method for using the compound for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combination comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and method for treating or preventing a HCV infection in a patient using the composition. The present invention is also used for treating or preventing HCV infection in a patient.


1196/2007 Vertex  
Pharmaceuticals  
Incorporated,  
USA

“A pharmaceutically acceptable salt or prodrug of a peptidomimetic compound, process for its preparation and a pharmaceutical composition comprising thereof”

A61K 13/00

**140117**

The present invention relates to peptidomimetic compound of formula I



useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; The invention is also directed to pharmaceutical composition and to method for using the compound for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combination comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and method for treating or preventing a HCV infection in a patient using the compositions. The present invention is also used for treating or preventing HCV infection in a patient.

1497/2007 Dr. Mansoor  
Ahmad,  
Department of  
Pharmacognosy,  
University of  
Karachi,  
Pakistan

“A novel herbal composition comprising *Lepidium meyenii*”

A61K 36/00

**140118**

The invention relates to a process for preparation of a novel herbal composition consisting of steps of collection of medicinal herbs *Lepidium meyenii* (maca), *Muira puama*, *Tribulus terrestris*, *Withania somnifera* (1Kg each) washing with water to remove dust, cutting into pieces by pair of scissors, putting into glass jars, methanol (1 liter each) was added to glass jars for 15 days for extraction, filtration of the liquid extract (4 liter) through filter paper, transferring to rotary flasks for concentration by means a rotary evaporator set at 40°C for approximately 30 hours for removal of extra methanol under reduced pressure, drying and powdering of the filtered extract at room temperature of 25°C, and addition of zinc and B vitamins as well as barley flour to this powdered extract to increase its shelf life.

1498/2007	Dr. Mansoor Ahmad, Department of Pharmacognosy, University of Karachi, Pakistan	“A novel herbal composition comprising foeniculum vulgare”	A61K 36/00	<b>140119</b>
		<p>The invention relates novel herbal composition consisting of steps of collection of medicinal herbs foeniculum vulgare, cuminum cyminum, cinnamomum iners, Citrus, Limon, Piper nigrum and Zingiber officinale (1Kg each) washing with water to remove dust, cutting into pieces by pair of scissors, putting into glass jars, methanol (1 liter each) was added to glass jars for 15 days for extraction, filtration of the liquid extract (7 liter) through filter paper, transferring to rotary flasks for concentration by means a rotary evaporator set at 40°C for approximately 30 hours for removal of extra methanol under reduced pressure, drying and powdering of the filtered extract at room temperature of 25°C , and addition of chickpea flour to this powdered extract to increase its shelf life.</p>		
246/2008	Honda Motor Co. Limited, Japan	“A rear structure of a vehicle body with a spare tire pan supported by a pair of rear frames”	B62D 25/20, B62D 43/10	<b>140120</b>
		<p>A rear structure of a vehicle body, where a spare tire pan is supported by rear frames extending substantially in the longitudinal direction of a vehicle body, includes a plurality of arc-shaped beads that is continued in a circular arc shape and formed on the spare tire pan. The plurality of arc-shaped beads is disposed so to be spaced apart from each other, and formed in a concave shape at substantially the same pitch toward the rear side of the vehicle body.</p>		
360/2008	Saudi Basic Industries Corporation, Saudi Arabia	“A combined reforming process for making a synthesis gas mixture suitable for methanol production”	CO1B 3/38, CO7C 29/151	

**140121**

The invention relates to a combined reforming process for making a synthesis gas mixture from a desulphurised methane-rich gaseous feedstock, wherein the gaseous feedstock is mixed with steam and passed through an adiabatic pre-reformer (APR), and wherein pre-reformed gas from the APR is divided into three streams that are fed to a steam methane reformer (SMR), a gas heated reformer (GHR) and to an auto-thermal reformer (ATR), which reforming reactors are operated in parallel.

The process of the invention enables to produce syngas with adjustable composition and at very high capacity in a single line. The process specifically allows designing a methane-to-methanol production plant with a capacity of at least 10000 mtpd using technically and economically feasible reforming equipment, and showing high feedstock and energy efficiency. The invention further relates to an integrated process for making methanol from a methane-rich gaseous feedstock comprising said combined reforming process.

751/2008 Bigtec Private Limited,  
India

“A process for preparation of biofuel comprising distilled cashew nut shell liquid and at least one petroleum product such as diesel and kerosene”

CO7C 31/08

**140122**

The present invention relates to a biofuel composition comprising distilled technical cashew nut shell liquid (DT-CNSL) and atleast one petroleum product optionally alongwith plant oils and fuel additive(s) . It also relates to a process for preparation of biofuel composition and a method of fueling biofuel composition.

757/2008 Sanofi-Aventis U.S. LLC,  
USA


“Process for the preparation of benzimidazol thienylamine compound”

CO7D 409/12, CO7D 333/36

**140123**

The present invention is an improved process for

the preparation of a sodium/proton exchange inhibitor of sub-type 3 (NHE-3) useful in the treatment of sleep apnea and other related respiratory disorders. The improved synthesis of the NHE-3 inhibitor, more specifically a benzimidazol thienylamine of the formula 1



utilizes novel reagents and chemical intermediate and thereby results in an improved yield and purity of the final product with less reaction or synthetic steps required.

1223/2008 Lt Col. (R) Mahmud “ A solid fuel stove”  
Shah,  
Lahore,  
Pakistan F24B 1/20

**140124**

A stove product is provided which burns compressed solid fuel in the form of tablets or pieces with facility to produce variations in its flame, which helps in cooking. The stove comprises of six components namely, PLATE, STAND, PAD, two PAD SUPPORTS and a WINDSHIELD. All components of the stove are made of metal sheet. The stove along with a bar of solid fuel tablets is packed in a small container. The stove is loose assembled by only placing components on top of each other. No nuts, bolts, hinges or hooks are used in its assembly. The PLATE, which is a square piece of metal sheet, is provided to form a firm and flat base for the stove. STAND is provided for placing the cooking pot and is made out of a rectangular strip of metal sheet with large size holes having length side much bigger than the width, and all sides at right angle to each other. It is formed by rolling up its length side and welding together the width sides with a little overlap. The PAD is provided for placing and welding together the width sides with a little overlap. The PAD is provided for placing and burning solid fuel in the form of tablet

or pieces. It is a circular disc of metal sheet with number of holes and metal spurs projecting outwards on one of its sides for keeping the solid fuel lifted up while burning. Two PAD SUPPORTS, which are strips of metal sheet with corrugated sharp cuts at two places on each of its length side edges and all four corners rounded up, are provided for placing and supporting PAD with solid fuel inside the STAND. These are placed in STAND by inserting in the middle line full circle holes, with a gap of one hole, side by side and parallel to each other with their flat side facing up. WINDSHIELD is provided for protecting the flame of solid fuel from wind. It is made of large size rectangular strip of metal sheet with its length side much bigger than the width, having all sides at right angle to each other and all the four corners rounded up. To deploy the WINDSHIELD, an oval shaped projection provided on one end of WINDSHIELD is inserted in a thin slit provided a little short of its other end, which gets locked, giving it a circular shape for placing around the stove during cooking.

**(MRS. YASMEEN ABBASI)**  
CONTROLLER OF PATENTS  
Tel: 9215488